Bought into this last Friday. RGS has got a great cash deal for one product in one market, and a JV partner who will assist in trials and licensing, regulatory etc.. On top of this there should be a good news flow over the next six months+ All up, what's not to like? Looks every bit as good, if not better than the CYP deal from what can be known about it.
